Fundz

Wave Life Sciences

Cambridge, United States · Biotechnology, Healthcare, Health Care

Wave Life Sciences (Nasdaq: WVE) is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of ster

Key facts

Headquarters
Cambridge, United States
Employees
341
Industries
Biotechnology, Healthcare, Health Care
Status
Public (WVE)
Website
wavelifesciences.com
LinkedIn
Company page

Recent activity at Wave Life Sciences

  • : Wave Life Sciences Partners with GSK to Advance Hepatology Candidate, Triggering $12 Million Milestone Payment.
  • : Wave Life Sciences Appoints Monika Vnuk as Chief Business Officer
  • : SEC 8-K (7.01): On July 30, 2026, Wave Life Sciences Ltd. updated its corporate presentation for the investment community, providing insights and summaries regarding its business. This update is available on the Company’s website and furnished as Exhibit 99.2 in the current report. The presentation serves to enhance transparency with stakeholders and may include key financial metrics and strategic initiatives. This update is part of the company’s ongoing efforts to improve communication with investors and stakeholders about its business operations.
  • : SEC 8-K (8.01):
  • : SEC 8-K (7.01): On April 28, 2026, Wave Life Sciences Ltd. updated its corporate presentation to inform the investment community about recent business developments. The updated presentation is available on their website and is also included as Exhibit 99.2 in this filing. This disclosure aims to enhance transparency and keep shareholders informed about the company's operations and strategies. The context of this update is essential for stakeholders who monitor company performance and outlook.
  • : SEC 8-K (8.01): On April 21, 2026, Wave Life Sciences Ltd. announced a hearing regarding its proposed redomiciliation to the United States in a press release. This redomiciliation process involves filing a definitive proxy statement with the SEC to inform its shareholders about the move from Singapore to the U.S. investors are urged to read the relevant documents as they will contain important information about the implications of this change. The filing indicates strategic efforts to enhance investor engagement and operational presence in the U.S., which could impact shareholder value and company operations significantly.
  • : SEC 8-K (1.01): On April 15, 2026, Wave Life Sciences Ltd. announced its decision to restructure its corporate group through a Redomiciliation, transitioning the parent company to a Delaware corporation. This was formalized by an Implementation Agreement executed on the same date between Wave-Singapore and its new parent Wave Life Sciences, Inc. The agreement involves a Scheme of Arrangement allowing for the exchange of Wave-Singapore Ordinary Shares for newly issued shares of common stock of Wave-Delaware on a one-for-one basis. Shareholder approval and High Court consent in Singapore are required for this transition, which will result in Wave-Singapore becoming a subsidiary of Wave-Delaware, with the aim to enhance corporate governance and operational efficiency. The press release about this restructuring was also made on April 15, 2026.
  • : SEC 8-K (8.01):
  • : SEC 8-K (7.01): On February 26, 2026, Wave Life Sciences Ltd. updated its corporate presentation to the investment community, providing important insights and summaries about its business activities. This updated presentation is part of the company's ongoing efforts to communicate developments to investors and is accessible on their website. The document was furnished as Exhibit 99.2 in the 8-K filing, emphasizing the company's transparency and commitment to keeping stakeholders informed. The communication does not hold the legal weight of filed documents under securities regulations, illustrating its purpose as informative rather than formal.
  • : SEC 8-K (8.01): On February 2, 2026, Wave Life Sciences Ltd. issued a press release announcing its plans to accelerate regulatory engagement concerning WVE-006, a therapeutic aimed at treating Alpha-1 Antitrypsin Deficiency. This strategic move indicates that Wave has secured full control over the product, which could significantly impact its development pathway and market potential. The press release, attached as Exhibit 99.1, suggests a renewed focus on accelerating the regulatory process, highlighting the importance of this initiative for investors and stakeholders in the biotech sector.

Wave Life Sciences funding history

DateRoundAmount
Aug 2015Venture$66.0M

Leadership

  • Monika Vnuk, Chief Business Officer
  • Chris Wright, Chief Medical Officer
  • Erik Ingelsson, Chief Scientific Officer
  • Erik Ingelsson, Chief Scientific Officer

Verified email and direct lines for Wave Life Sciences’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Wave Life Sciences in the news

Companies similar to Wave Life Sciences

About Wave Life Sciences: questions and answers

What does Wave Life Sciences do?

Wave Life Sciences (Nasdaq: WVE) is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of ster

Where is Wave Life Sciences headquartered?

Wave Life Sciences is headquartered in Cambridge, United States.

How many employees does Wave Life Sciences have?

Wave Life Sciences has about 341 employees.

Has Wave Life Sciences raised funding?

Yes. Fundz has recorded 1 funding event for Wave Life Sciences. The most recent, $66.0M, was in Aug 2015.

What is the latest news on Wave Life Sciences?

On Sep 30, 2026, Wave Life Sciences Partners with GSK to Advance Hepatology Candidate, Triggering $12 Million Milestone Payment.

Is Wave Life Sciences a public company?

Yes. Wave Life Sciences is publicly traded under the ticker WVE.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Wave Life Sciences across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.